Clinical trial
Corneal Versus Conjunctival Delivery Using a Delivery Device
NCT00143429 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00143429 |
|---|---|
| Title | Corneal Versus Conjunctival Delivery Using a Delivery Device |
| Official title | Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glaucoma, Open-Angle, Ocular Hypertension |
| Intervention type | Drug |
| Interventions | Xalatan |
| Enrollment | 0 |
| First posted | Sep 2, 2005 |
| Last update posted | Feb 2, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: